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Abstract
Purpose: In SBRT for prostate cancer, higher fractional dose to the rectum is a
major toxicity concern due to using smaller PTV margin and hypofractionation. We
investigate the dosimetric impact on rectum using endorectal balloon (ERB) in pros-
tate SBRT.
Materials and Methods: Twenty prostate cancer patients were included in a retro-
spective study, ten with ERB and 10 without ERB. Optimized SBRT plans were gen-
erated on CyberKnife MultiPlan for 5 9 7.25 Gy to PTV under RTOG-0938
protocol for early-stage prostate cancer. For the rectum and the anterior half rec-
tum, mean dose and percentage of volumes receiving 50%, 80%, 90%, and 100%
prescription dose were compared.
Results: Using ERB, mean dose to the rectum was 62 cGy (P = 0.001) lower per
fraction, and 50 cGy (P = 0.024) lower per fraction for the anterior half rectum. The
average V50%, V80%, V90%, and V100% were lower by 9.9% (P = 0.001), 5.3%
(P = 0.0002), 3.4% (P = 0.0002), and 1.2% (P = 0.005) for the rectum, and lower by
10.4% (P = 0.009), 8.3% (P = 0.0004), 5.4% (P = 0.0003), and 2.1% (P = 0.003) for
the anterior half rectum.
Conclusions: Signiﬁcant reductions of dose to the rectum using ERB were observed.
This may lead to improvement of the rectal toxicity proﬁles in prostate SBRT.
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1 | INTRODUCTION
Based on the evidence of prostate cancer having a relatively low a/b
ratio1–3 and the signiﬁcantly improved accuracy in image-guided target
localization and radiation dose delivery,4–6 hypofractionated stereo-
tactic body radiation therapy (SBRT) for prostate cancer has been
investigated at multiple institutions.7–12 These works have demon-
strated that prostate SBRT can result in effective biochemical control
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while minimizing rectal and bladder toxicities to a level that is compa-
rable to those seen in conventional radiotherapy, including 3D-CRT
(3D Conformal Radiation Therapy), IMRT (Intensity Modulated
Radiation Therapy), and HDR (High Dose Rate Brachytherapy). With
the follow-up data approaching 6 years to this date, prostate SBRT
has now been considered as an alternative therapeutic option to the
conventional radiotherapy for localized prostate cancer, either as a
monotherapy for low- and intermediate-risk prostate cancer13–16 or
post-IMRT boost treatment for high-risk prostate cancer.17
In SBRT for prostate cancer, due to the much higher dose per
fraction and use of smaller PTV margins (2–3 mm posterior, 3–5 mm
in all other directions) than those in 3D-CRT or IMRT, it is particu-
larly critical to minimize the prostate motion and the exposure of
rectum volumes to intermediate and high dose which are predictive
factors for late rectal toxicity.18–20 It has been shown that an air or
water-ﬁlled endorectal balloon (ERB) can signiﬁcantly reduce pros-
tate motion21–23 and displace the posterior portion of the rectal wall
away from the intermediate-to-high dose regions in 3D-CRT and
IMRT. This displacement can lead to signiﬁcant rectal wall sparing
and reducing rectal toxicity from prostate or post-prostatectomy
radiation treatment, potentially to allow for further dose escalation
to the prostate.24–30
For prostate SBRT, late rectal toxicity data are very limited with
maximum follow-up just under 6 years.14–16 It can be anticipated
that any systematic reduction of rectal dose in such hypofraction-
ated prostate treatment may be beneﬁcial, such as those potentially
achievable using ERB to minimize exposing rectal volume to interme-
diate and high dose. However, to this date, there has been no speci-
ﬁc study based on CyberKnife prostate SBRT experience on how
using ERB may help to reduce rectum dose and improve rectal dose-
volume proﬁles under the hypofractionated target dose speciﬁca-
tions and OARs (organ-at-risk) constraints. In addition, use of ERB
has not been included neither on protocols treating prostate alone
for early-stage prostate cancer nor on protocols treating both the
prostate and the proximal seminal vesicles for intermediate-risk and
high-risk prostate cancer.
In this work, we performed a systematic treatment planning
study on the potential dosimetric impacts of using ERB for prostate
cancer patients who may receive SBRT treatments such as those
described in RTOG-0938 “A Randomized Phase II Trial of Hypo-
fractionated Radiotherapy for Favorable Risk Prostate Cancer”.31
2 | MATERIALS AND METHODS
2.A | Patient data and use of ERB
Twenty prostate cancer patient cases previously treated at two insti-
tutions were selected for a retrospective CyberKnife SBRT treatment
planning study. Ten of the patients had CT simulation and treatment
using ERB ﬁlled with 60–100 cc water (the ERB group). The other
ten patients had CT simulation and treatment with empty rectum
and no ERB (the noERB group). Figure 1 shows the endorectal bal-
loon (ERB) used for patients included in this planning study.
All patients had at least three well-spaced ﬁducials implanted in
the prostate for image-guided target volume localization. For patient
in the ERB group, immediately before CT simulation scan, an indexed
lumen ERB (RadiaDyne, LLC, Houston, TX, USA) was inserted into the
rectum, ﬁlled with 60–100 cc water so that their density would be
essentially homogeneous with that of the surrounding tissue. For
patients in the noERB group, instructions were given for pre-CT and
pretreatment bowel preparation, including dietary guidelines, use of
anti-gas tablets, and administered enemas to ensure an empty rectum.
2.B | SBRT planning and dosimetric comparison
The gross tumor volume (GTV) for this study refers to the pros-
tate alone per RTOG-0938 protocol for early-stage prostate can-
cer. The clinical target volume (CTV) was the same as the GTV
consisting of the prostate alone without including the seminal
vesicles. Prostates were drawn by two radiation oncologists using
the noncontrast axial CT scans for planning. The planning target
volume (PTV) was deﬁned as the CTV plus a 3 mm margin poste-
riorly and 5 mm in all other directions. Normal tissue organs such
as bladder and rectum were contoured as solid organs instead of
contouring the bladder and rectal walls. The bladder was con-
toured from its base to the dome. The rectum was contoured
from the anus at the level of the ischial tuberosities to the recto-
sigmoid ﬂexure, generally below the bottom of the sacroiliac
joints. Because the anterior half of the rectum is in touch or in
overlap with the prostate PTV and more subject to intermediate-
to-high dose, it was contoured by bisecting the rectum contour
into the anterior half and the posterior half slice-by-slice and eval-
uated separately for comparison.
An optimized SBRT plan was generated for each case using the
multi-objective sequential optimization in CyberKnife MultiPlan TPS
system to meet the ﬁve fraction (5 9 725 cGy) dose-speciﬁcation
and dose-volume constraints per RTOG-0938 for early-stage pros-
tate cancer. These plans typically used 2–3 collimators of different
sizes, and 100–200 noncoplanar and nonisocentric beams of 6 MV x
ray. Target dose coverage was characterized by the new conformity
index (nCI), heterogeneity index, and mean PTV dose. Plans were
typically prescribed to 79%–85% isodose line (IDL) to ensure that at
least 95% of the PTV was covered by the prescription dose. Dosi-
metric parameters for the rectum and the anterior half of the rectum
were compared between the two groups, including the mean dose
F I G . 1 . The endorectal balloon (ERB) used for patients included in
this planning study.
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and the percentages of volume receiving 50%, 80%, 90%, and 100%
of the prescription dose.
2.C | Statistical analysis
Descriptive statistics were calculated for each dosimetric parameter
in the ERB group and noERB group. Mean and standard deviation
are reported along with the difference in mean value for each
parameter and denoted as D. Independent samples t-tests were
performed to examine the differences between the two groups.
The analyses were repeated after logarithmic (lg 10) transformation
of the dosimetric data. All statistical analyses were performed
using the SPSS software for Windows (version 20.0, SPSS Inc.,
Chicago, IL, USA). Differences with P-value <0.05 was considered
statistically signiﬁcant.
3 | RESULTS
Figure 2 shows the isodose distributions for a case from the ERB
group (left) and a case from the noERB group (right). It demonstrates
that rectal volumes receiving intermediate-to-high dose (18.3–
36.25 Gy, i.e., 50–100% of the prescription dose 36.25 Gy) was
reduced using ERB.
F I G . 2 . Typical dose distributions of
CyberKnife prostate SBRT plans for a case
from the ERB group (left) and a case from
the noERB group (right). The top row for
axial view, bottom row for sagittal view.
The anterior half of the rectum contours
were obtained by bisecting the full rectum
contours from the midline slice-by-slice.
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F I G . 3 . DVHs for a typical case in the ERB group (a) and in the noERB group (b).
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Figure 3 shows the dose-volume histograms (DVHs) for rectum
and the anterior half rectum in the two typical cases, with the ERB
case (left: a) having lower proﬁles than the noERB case (right: b).
Blue for prostate, red for PTV, green for rectum, and black for the
anterior half of the rectum. This rectal sparing effect is similar to
what was reported in 3D-CRT and IMRT studies using ERB, which
was caused by the expansion of the whole rectum and the displace-
ment of the rectum walls laterally and posteriorly away from the
intermediate-to-high dose region.
Table 1 shows the plan dosimetric characteristics for the ERB
group versus noERB group, including the volumes of the prostate
(CTV) and PTV, mean dose to PTV, PTV volume coverage in % by pre-
scription dose, dose conformity index, dose heterogeneity index, and
plan prescription isodose line. For target, all cases have at least 95% of
the PTV covered by prescription dose of 36.25 Gy, with median of the
PTV mean dose at 39.9 Gy (range 38.9–40.8 Gy) for the ERB group,
and median of the PTV mean dose at 39.8 Gy (range 39.2–40.6 Gy)
for the noERB group. Overall, target volumes and their dosimetric
characteristics are comparable between the two groups.
Table 2 shows the comparison of the dosimetric parameters for
rectum volumes and the anterior half rectum volumes between the
ERB group and the noERB group. Vx%, (x% = 50%, 80%, 90%, 100%)
represent the percentage volumes exposed to x% of the prescription
dose (36.25 Gy) for the rectum volumes and the anterior half rectum
volumes.
As shown in Table 2, mean dose to the rectum was signiﬁcantly
lower for the ERB group (mean 10.4 Gy) than the noERB group (mean
13.5 Gy), an average reduction of 3.1 Gy (P = 0.001), or 62 cGy lower
per fraction (P = 0.001). Similarly, mean dose to the anterior half rec-
tum was also signiﬁcantly lower for the ERB group (mean 14.9 Gy)
than the noERB Group (mean 17.4 Gy), an average reduction of
2.5 Gy ((P = 0.024), or 50 cGy lower per fraction (P = 0.024).
A pattern of signiﬁcant reduction in rectum volumes (in percent-
age) receiving 50%, 80%, 90%, and 100% of prescription dose
(36.25 Gy) was seen between the ERB Group and the noERB Group.
The average V50%, V80%, V90%, and V100% for the ERB Group were
18.1%, 6.9%, 3.9%, and 1.0% in comparison to 28.0%, 12.2%, 7.3%,
and 2.2% for the noERB group, a reduction of 9.9% (P = 0.001), 5.3%
(P = 0.0002), 3.4% (P = 0.0002), and 1.1% (P = 0.005), respectively.
Further, a pattern of more notable reduction in anterior half rec-
tum volumes (in percentage) receiving 50%, 80%, 90%, and 100% of
prescription dose (36.25 Gy) was observed between the ERB Group
and the noERB Group. The average V50%, V80%, V90%, and V100% for
the ERB Group were 33.0%, 12.7%, 7.2%, and 1.8% in comparison
to 43.4%, 21.0%, 12.6%, and 3.9% for the noERB group, a signiﬁcant
reduction of 10.4% (P = 0.009), 8.3% (P = 0.0004), 5.4%
(P = 0.0003), and 2.1% (P = 0.003), respectively.
Similar results were obtained when the analyses were repeated
on logarithmic-transformed data. All the above comparisons
remained statistically signiﬁcant (data not shown).
Figure 4 shows the DVH proﬁle comparison between the ERB
group and the noERB group for the rectum (left) and the anterior
half rectum (right) in the intermediate-to-high dose region for the
prescription dose of 36.25 Gy (5 9 7.25 Gy). Data points are







Median Range Median Range
Prostate (cc) 40.0 16.6–87.4 44.7 22.8–87.1
PTV (cc) 79.3 41.6–151.5 80.7 48.3–143.7
Conformality Index 1.18 1.11–1.25 1.18 1.09–1.28
Heterogeneity Index 1.23 1.18–1.25 1.23 1.20–1.27
Rx Isodose Line 81% 80%–85% 81% 79%–83%
PTV coverage 96% 95%–98% 96% 95%–97%
PTV mean dose
(cGy)
3987 3893–4077 3982 3915–4062
ERB, Endorectal balloon; N, number of patients; PTV, planning target vol-
ume; Rx, prescription.
TAB L E 2 Comparison of the dosimetric characteristics for the rectum and the anterior half rectum volumes.
Volumes DVH Metrics
ERB Group (N = 10) noERB Group (N = 10)
Δ P-ValueMean  SD (Range) Mean  SD (Range)
Rectum Mean dose (Gy) 10.4  1.8 8.2–13.5 13.5  1.9 11.1–16.6 3.1 0.001
V50% (%) 18.1  4.8 12.0–24.8 28.0  6.8 18.1–40.7 9.9 0.001
V80% (%) 6.9  1.9 3.8–9.2 12.2  3.2 7.5–16.8 5.3 0.0002
V90% (%) 3.9  1.1 1.9–5.2 7.3  2.0 3.7–9.5 3.4 0.0002
V100% (%) 1.0  0.4 0.4–1.7 2.2  1.1 0.7–3.9 1.1 0.005
Anterior rectum wall Mean dose (Gy) 14.9  2.5 11.6–19.6 17.4  2.0 14.7–20.2 2.5 0.024
V50% (%) 33.0  8.7 23.3–48.6 43.4  7.2 33.2–54.2 10.4 0.009
V80% (%) 12.7  3.4 7.8–17.9 21.0  5.0 14.0–28.0 8.3 0.0004
V90% (%) 7.2  1.9 3.8–9.9 12.6  3.4 6.4–16.9 5.4 0.0003
V100% (%) 1.8  0.6 1.0–2.8 3.9  1.9 1.2–6.8 2.1 0.003
DVH, Dose-volume histogram; ERB, Endorectal balloon; N, number of patients; SD, standard deviation; D, Difference between mean noERB and ERB
values.
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the averaged percentage volumes at 50%, 80%, 90%, and 100% of
the prescription dose.
4 | DISCUSSION
4.A | Signiﬁcance of rectum dose reduction for
SBRT
Using ERB to reduce dose to anorectal wall has been reported on
3D-CRT and IMRT for prostate cancer. Patel et al. 30 ﬁrst reported
that using ERB in 3D-CRT of 38 9 2.0 Gy led to signiﬁcant high-
dose rectal sparing comparable to that achieved by a highly confor-
mal IMRT of 38 9 2.0 Gy. Further sparing can be achieved in IMRT
using rectal balloon. An overall average rectal sparing ratio (RSR) of
0.61, that is, a mean fractional high-dose rectal sparing of 39%, was
reported for rectal volumes receiving ≥65 Gy (RSR is deﬁned as rec-
tum’s high dose volume with ERB inﬂated, divided by the volume
with ERB deﬂated). VanLin et al. 29 reported that in both 3D-CRT
and IMRT, using ERB can lead to signiﬁcant dose reduction for rec-
tum exposed to intermediate and high dose. Smeenk et al. 27
reported a 12 Gy mean dose reduction for the anal wall in 3D-CRT
of 39 9 2 Gy, and a 7.5 Gy mean dose reduction in IMRT of
39 9 2 Gy.
This study is the ﬁrst, to the best of our knowledge, to show
that a systematic dose reduction effect also exists for CyberKnife-
based prostate SBRT under the extreme hypofractionation of
5 9 7.25 Gy for treating early-stage prostate cancer. Due to the
much higher dose per fraction, the magnitude of per fraction rectal
dose reduction in SBRT may bear more signiﬁcance in relation to
both the acute and the late rectal toxicity than those seen for 3D-
CRT or IMRT. In terms of absolute dose, using ERB in SBRT of
5 9 7.25 Gy was shown to have an average 3.1 Gy lower mean
dose to the rectum, and an average 2.5 Gy lower mean dose to the
anterior half rectum. This appears to be smaller magnitude of reduc-
tion than the 7.5–12.0 Gy mean dose reduction seen in 3D-CRT and
IMRT of 39 9 2.0 Gy.27 However, in terms of fractional dose reduc-
tion, the 2.5–3.1 Gy overall reduction in SBRT is 50–60 cGy reduc-
tion per fraction; this is a much higher dose reduction per fraction
than those seen in 3D-CRT and IMRT of 20–30 cGy dose reduction
per fraction.27
The rectum dose reduction we have seen between patients
planned with ERB and noERB is a meaningful ﬁnding in the context
of extreme hypofractionated CyberKnife prostate SBRT of 36.25 Gy
in ﬁve fractions. These results and the effective plan optimization
technique may turn out to be even more important in view of the
more recent interests in prostate focal therapy approach by generat-
ing a simultaneously integrated dose escalation to 47.5 Gy onto the
dominant intra-prostatic lesion while maintaining the 36.25 Gy to
the prostate gland.32,33
A recent study by Wong, et al. reported an increase in the vol-
ume of rectum and rectal wall receiving high-dose radiation using an
ERB during SBRT in the form of RapidArc volumetric modulated arc
therapy (VMAT) using 6 MV ﬂattering ﬁlter-free photon beams. This
observation differs from the results in our study using 6 MV photon
beams on CyberKnife for SBRT, as well as the general rectum dose
reductions seen in previous studies with 3D-CRT and IMRT.27, 29, 30
This difference may be related to two important points emphasized
in our study. First, in planning, we strictly followed the RTOG 0938
planning DVHs constraint guidelines, especially the DVH constraints
for rectal volumes receiving high doses, V3806 < 1 cc (3806 cGy
corresponding to 105% of the prescription dose of 3625 cGy) and
V3440 < 3 cc (corresponding to 95% of the prescription dose). Our
results showed similar V100% of both the rectum volume and the
anterior rectum volume for the ERB group vs. the noERB group, as
revealed in Fig. 4. Second, the use of non-coplanar and non-iso-
centric beams from CyberKnife physically offered a better rectal
sparing dosimetry advantage as there are no posterior beams going
through rectum, and there are only anterior and anterior oblique
beamlets in CyberKnife-based SBRT in comparison to the beams
used in gantry-based RapidArc(VMAT) SBRT.
4.B | On the study design regarding patient data
group selection
It should be pointed out that unlike those done in previous studies
for 3D-CRT and IMRT, as well as the recent study for SBRT by
Wong, et al.,34 patient data included in this study were not repeated
CT scans of same group of patients with ERB versus noERB. Theo-
retically, a more rigorous controlled comparison would be helpful to
provide direct insight by selecting the same group of patients, with
repeated CT scans once with ERB and once without ERB. Unfortu-
nately, at the start of this study, the potential dosimetric beneﬁt of
using ERB was not clear because of the lacking of such comparison
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F I G . 4 . DVHs proﬁles for the rectum
volume (left) and anterior half rectum
volume (right) in the intermediate-to-high
dose region 50%–100% of prescription
dose 36.25 Gy.
XIANG ET AL. | 41
Instead, we collected data from two separate patient groups: one
used EBR, and the other did not use ERB per institution protocol
acceptance. We chose to compare the two groups’ dosimetric pro-
ﬁles for the percentage rectum volumes receiving intermediate-to-
high doses. This approach echo the general methodology used in
randomized clinical trials where two patient groups of the same dis-
ease proﬁle were randomized to go through different treatment
schemes for comparison.
Our study intent is to examine the general proﬁles of the rectum
mean dose and dose-volume histograms of the two patient groups,
though not ideally having each patient’s consecutive CT scans with
one having ERB and the other with no ERB. Nevertheless, as shown in
Table 1, the two groups have similar target volume and dosimetry char-
acteristics, and were both planned under the dose-speciﬁcation and
dose-volume constraints of a common SBRT protocol RTOG 093831 of
hypofractionated RT for early-stage prostate cancer. Therefore, our
approach also provides clinically relevant and useful comparison.
4.C | Rectum DVHs and toxicity proﬁles in
prostate SBRT
Recently, King et al. reviewed patient health related QoL (Quality-of-
Life) follow-up after SBRT for 864 patients of localized prostate can-
cer.15 Rectum toxicity proﬁles at median follow-up of 3 yr for late
grade 3 GI (gastrointestinal) toxicities typically lies within the 1%–3%
range, which is comparable to those seen in conventionally fraction-
ated 3D-CRT, IMRT, or HDR. The rectum DVH objectives in these
prostate SBRT are generally V50% <50% (rectum volume receiving
50% of the prescribed dose is <50%), V80% <20%, V90% <10%, and
V100% <5%.
11,12,15,16 Our study demonstrated a pattern of system-
atic improvements in DVH proﬁles of the rectum using ERB as seen
in Table 2, Figs. 3 and 4. The rectum DVHs for both the ERB and
the noERB group are much better than the general objectives in the
review.15 In addition, we also examined the DVH proﬁles for the
anterior half rectum volumes. The exposure of the anterior half rec-
tum to intermediate-to-high dose bears more relevance in evaluating
rectal toxicity in SBRT.
Unlike in IMRT or 3D-CRT of 79.2 Gy where a 15% rectum
volume receiving dose greater than 70 Gy is known to be an inde-
pendent predictor for late grade 2 rectal toxicity,20 there has been
no established upper limit in prostate SBRT for rectum DVHs based
on analyzing clinical data in the intermediate-to-high dose region. In
evaluating prostate SBRT treatment and rectal toxicity, mean dose
and DVHs proﬁles of rectum, especially the anterior half of the rec-
tum, should be minimized to ALARA (As Low As Reasonably Achiev-
able) while respecting the relatively general objectives for rectum
DVHs.15 Overall, this study showed systematically better DVH pro-
ﬁles for rectum using ERB. Potentially, such dosimetric improve-
ments may lead to better rectal toxicity proﬁles for SBRT treatment;
yet, this hypothesis remains to be examined with clinical follow-up
data when it becomes available.
It should be noted that this study is limited to SBRT planning for
early-stage prostate cancer where the CTV is deﬁned as prostate
volume alone without including the seminal vesicles (SV). This may
explain why in general we achieved overall much better rectum
DVH proﬁles (as seen in Table 2 and Fig. 3) than those described by
King et al.15 This can be due to the fact that smaller section of the
rectum is involved when CTV includes prostate alone. Patel et al.30
reported signiﬁcant rectal sparing using ERB in IMRT for ﬁve
patients with and without inclusion of seminal vesicles. In compar-
ison, they observed signiﬁcant (about 10% more) rectal sparing in
terms of reducing rectum volumes receiving intermediate-to-high
dose of 55–70 Gy for plans with prostate alone in CTV than those
with both prostate and SV in CTV. As a next step, we will extend
our analysis to cases of intermediate risk and high risk by including
the proximal section of the seminal vesicles into the CTV to charac-
terize the potential dosimetry improvement using ERB.
5 | CONCLUSIONS
In conclusion, signiﬁcant reductions of dose to the rectum using ERB
were observed in the intermediate and high-dose region from a ret-
rospective planning study of CyberKnife prostate SBRT. This may be
considered as a valuable technique for clinical implementation to
improve the rectal toxicity proﬁles in prostate SBRT.
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